{
    "organizations": [],
    "uuid": "30e041ab1ab17a50ccf001bae9129fdd68d77a0d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncolytics-biotech-reports-qtrly-b/brief-oncolytics-biotech-reports-qtrly-basic-and-diluted-loss-per-common-share-of-0-03-idUSASC0A1QX",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncolytics Biotech Reports Qtrly Basic And Diluted Loss Per Common Share Of $0.03",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 11 (Reuters) - Oncolytics Biotech Inc:\n* ONCOLYTICS BIOTECH® REPORTS 2018 FIRST QUARTER RESULTS * ONCOLYTICS BIOTECH INC - QTRLY BASIC AND DILUTED LOSS PER COMMON SHARE $0.03\n* ONCOLYTICS BIOTECH INC - AT MARCH 31, 2018, CO REPORTED $7.7 MILLION IN CASH AND CASH EQUIVALENTS\n* ONCOLYTICS BIOTECH INC - ALL DOLLAR AMOUNTS ARE CANADIAN\n* ONCOLYTICS - ADVANCED PLANS TO RELIST CO’S SHARES ON NASDAQ CAPITAL MARKET EXCHANGE, CONTINUES TO EVALUATE TIMING OF THIS ACTION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T19:10:00.000+03:00",
    "crawled": "2018-05-12T17:28:28.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "oncolytics",
        "biotech",
        "inc",
        "oncolytics",
        "report",
        "first",
        "quarter",
        "result",
        "oncolytics",
        "biotech",
        "inc",
        "qtrly",
        "basic",
        "diluted",
        "loss",
        "per",
        "common",
        "share",
        "oncolytics",
        "biotech",
        "inc",
        "march",
        "co",
        "reported",
        "million",
        "cash",
        "cash",
        "equivalent",
        "oncolytics",
        "biotech",
        "inc",
        "dollar",
        "amount",
        "canadian",
        "oncolytics",
        "advanced",
        "plan",
        "relist",
        "co",
        "share",
        "nasdaq",
        "capital",
        "market",
        "exchange",
        "continues",
        "evaluate",
        "timing",
        "action",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}